Rokit Healthcare Moves to End U.S. Distributor Deal After FDA Warning

Rokit Healthcare said it is terminating its U.S. distribution deal with Tides Medical after an FDA warning letter, according to En. The company said the warning letter stemmed from marketing rather than the product.

U.S. distribution deal set to end

En reported that Rokit Healthcare is moving to end its distribution arrangement with Tides Medical in the United States. The reported action follows an FDA warning letter cited by the company in explaining its decision.

Rokit Healthcare characterized the issue behind the letter as marketing-related. According to En, the company said the warning letter did not stem from the product.

Marketing is central to the company’s response

The report places marketing at the center of Rokit Healthcare’s stated explanation for ending the distributor deal. For medical sales professionals, the development highlights the role promotional activity can play in a regulatory event involving a distribution relationship.

En’s report distinguishes between the company’s account of the marketing issue and its position on the product. Rokit Healthcare said the FDA warning letter stemmed from marketing, not product, according to the publisher.

Reported points

• Rokit Healthcare said it is terminating its U.S. distribution deal with Tides Medical.
• The decision followed an FDA warning letter, En reported.
• Rokit Healthcare said the letter stemmed from marketing rather than the product.

Distributor relationships in the regulatory context

The reported move connects an FDA warning letter with a decision affecting Rokit Healthcare’s U.S. distributor arrangement. En identified Tides Medical as the distributor involved and reported that Rokit Healthcare is moving to end the deal.

Rokit Healthcare’s statement, as summarized by En, focused on the source of the warning letter. The company said marketing, rather than the product, was the basis for the issue. The report does not add further detail on the marketing activity or the terms of the distribution agreement.

Medical sales teams and distributor-facing professionals can note the company’s stated distinction as they follow this regulatory and channel-development event. En published its report on October 22, 2026.